Menu Search
Equities

Palisade Bio Inc

  • Add to watchlist
  • Add to portfolio
7NS0:DEU

Palisade Bio Inc

Actions
  • Price (EUR)4.91
  • Today's Change0.00 / 0.00%
  • Shares traded1.11k
  • 1 Year change--
  • Beta1.3132
Data delayed at least 15 minutes, as of Apr 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

  • Revenue in USD (TTM)0.00
  • Net income in USD-13.14m
  • Incorporated2001
  • Employees8.00
  • Location
    Palisade Bio Inc7750 El Camino Real, Suite 5200CARLSBAD 92009United StatesUSA
  • Phone+1 (858) 704-4900
  • Fax+1 (302) 697-4597
  • Websitehttps://palisadebio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.